Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement

The National Institute for Health and Clinical Excellence (NICE) has thus far relied on historical data and predominantly industry-sponsored trials to provide evidence for venous thromboembolic (VTE) prophylaxis in joint replacement patients. We argue that the NICE guidelines may be reliant on assum...

Descripción completa

Detalles Bibliográficos
Autores principales: Jameson, S. S., Baker, P. N., Deehan, D. J., Port, A., Reed, M. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: British Editorial Society of Bone and Joint Surgery 2014
Materias:
Annotation: Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054010/
https://www.ncbi.nlm.nih.gov/pubmed/24837005
http://dx.doi.org/10.1302/2046-3758.35.2000225
Descripción
Sumario:The National Institute for Health and Clinical Excellence (NICE) has thus far relied on historical data and predominantly industry-sponsored trials to provide evidence for venous thromboembolic (VTE) prophylaxis in joint replacement patients. We argue that the NICE guidelines may be reliant on assumptions that are in need of revision. Following the publication of large scale, independent observational studies showing little difference between low-molecular-weight heparins and aspirin, and recent changes to the guidance provided by other international bodies, should NICE reconsider their recommendations? Cite this article: Bone Joint Res 2014;3:146–9.

Ejemplares similares